Scarica l'app Stockscreener
91.41
3.61%
-3.42
Dopo l'orario di chiusura:
91.41
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Assessing Protagonist Therapeutics (PTGX) Valuation After Strong Recent Share Price Momentum - simplywall.st
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - AOL.com
Is Protagonist Therapeutics (PTGX) Still Attractive After A 136% One Year Share Price Surge - simplywall.st
JPMorgan Chase & Co. Lowers Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) Target Price Raised by Goldman S - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $95.00 - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Strong Buy Ratings and a Promising 14.42% Upside Potential - DirectorsTalk Interviews
TD Asset Management Inc Acquires 34,096 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wedbush Raises Price Target on Protagonist Therapeutics to $100 From $86, Keeps Outperform Rating - marketscreener.com
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - lelezard.com
Takeda Pharmaceutical and Protagonist Therapeutics Inc (NASDAQ: PTGX) jointly announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for their co-developed drug Rusfertide and granted it prior - Bitget
HC Wainwright Has Optimistic Outlook of PTGX Q1 Earnings - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Vanguard Group Inc. - MarketBeat
Citigroup Inc. Has $10.14 Million Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift - Yahoo Finance
Protagonist Therapeutics (PTGX) Quarterly Loss Deepens To US$44.4m And Tests Bullish Profitability Narrative - Sahm
PTGX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance - AOL.com
A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts - Sahm
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines - TipRanks
Understanding the Setup: (PTGX) and Scalable Risk - Stock Traders Daily
Protagonist Therapeutics (PTGX) Gets Price Target Lift from TD C - GuruFocus
TD Cowen Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $100.00 - MarketBeat
PTGX: Today's Analyst Ratings and Price Target Updates | PTGX St - GuruFocus
Protagonist Therapeutics (PTGX) Sees Analyst Rating Update from Barclays | PTGX Stock News - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $113.00 at Barclays - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $112.00 - MarketBeat
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit - AOL.com
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Desert Sun
Citizens raises Protagonist Therapeutics stock price target on drug approvals - Investing.com UK
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Register-Guard
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Protagonist Therapeutics: Fourth Quarter Earnings Overview - Bitget
Protagonist Therapeutics: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - FinanzNachrichten.de
Protagonist Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Protagonist Therapeutics Q4 revenue drops on lower milestone payments - TradingView
Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q4 Revenue $7.4M - marketscreener.com
[8-K] Protagonist Therapeutics, Inc Reports Material Event | PTGX SEC FilingForm 8-K - Stock Titan
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit - The Motley Fool
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: A Promising Biotech with 17.7% Upside Potential - DirectorsTalk Interviews
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026 - ACCESS Newswire
HC Wainwright raises Protagonist Therapeutics, Inc. (PTGX) target to $117, reiterates buy - MSN
RTW INVESTMENTS, LP Reduces Stake in Protagonist Therapeutics Inc - GuruFocus
Can Protagonist Therapeutics Inc. sustain its profitabilityWeekly Trade Summary & AI Driven Stock Movement Reports - mfd.ru
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):